Mauro David J
Known title: Chief Medical OfficerCIK: 0001621172
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
PRLD announces collaboration and supply deal with Eli Lilly. Prelude Therapeutics disclosed a collaboration and supply agreement with Eli Lilly. The arrangement will have Prelude provide its CDK4/6 inhibitor abemaciclib and oral estrogen receptor antagonist imlunestrant for Lilly‑led clinical trials. Partnering with a large pharmaceutical company may expand Prelude's development pipeline and potential revenue sources. The stock is currently near its long‑term support level.
Transaction History
| RXRX | ▼ Sell | Tax Withholding | 4,187 | $26K | 11/15/2024 | View on chart |
| RXRX | ▼ Sell | Tax Withholding | 14,146 | $95K | 8/15/2024 | View on chart |
| RXRX | ▼ Sell | Tax Withholding | 867 | $9K | 5/15/2024 | View on chart |
| RXRX | ▼ Sell | Tax Withholding | 1,892 | $19K | 2/9/2024 | View on chart |
| RXRX | ▲ Buy | Grant | 49,768 | $0 | 2/9/2024 | View on chart |
| RXRX | ▲ Buy | Grant | 6,040 | $0 | 2/9/2024 | View on chart |
| RXRX | ▲ Buy | Grant | 190,713 | $0 | 6/1/2023 | View on chart |
| PRLD | ▲ Buy | Option Exercise | 15,000 | $28K | 10/5/2021 | View on chart |
| PRLD | ▼ Sell | Open Market | 5,908 | $179K | 10/5/2021 | View on chart |
| PRLD | ▼ Sell | Open Market | 7,803 | $244K | 10/5/2021 | View on chart |
| PRLD | ▼ Sell | Open Market | 1,289 | $41K | 10/5/2021 | View on chart |
| PRLD | ▲ Buy | Option Exercise | 15,000 | $28K | 9/7/2021 | View on chart |
| PRLD | ▼ Sell | Open Market | 7,487 | $269K | 9/7/2021 | View on chart |
| PRLD | ▼ Sell | Open Market | 2,873 | $106K | 9/7/2021 | View on chart |
| PRLD | ▼ Sell | Open Market | 4,640 | $175K | 9/7/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Recursion Pharmaceuticals Stock Falls as Cathie Wood Adjusts Biotech Holdings
Recursion Pharmaceuticals shares have declined recently while the broader market improved. This movement coincides with Cathie Wood's recent portfolio adjustments, where she increased positions in several biotech stocks while reducing others. The stock is currently trading near the middle of its 52-week range, with analysts maintaining an average target price of $7.22.
Recursion Pharmaceuticals Stock Falls as Cathie Wood Adjusts Biotech Holdings. Recursion Pharmaceuticals shares have declined recently while the broader market improved. This movement coincides with Cathie Wood's recent portfolio adjustments, where she increased positions in several biotech stocks while reducing others. The stock is currently trading near the middle of its 52-week range, with analysts maintaining an average target price of $7.22.